Proposed Information Collection Activity; Title IV-E Programs Quarterly Financial Report (0970-0510), 68907-68908 [2024-19253]

Download as PDF Federal Register / Vol. 89, No. 167 / Wednesday, August 28, 2024 / Notices Proposed FY25 awards (subject to availability of funding) Recipient name California Department of Public Health ............................................................................................... Chicago Department of Public Health ................................................................................................. Delaware Health and Social Services ................................................................................................. Florida Department of Health .............................................................................................................. Georgia Department of Public Health ................................................................................................. Houston Health Department ................................................................................................................ Illinois Department of Public Health .................................................................................................... Indiana State Department of Health .................................................................................................... Los Angeles County Department of Public Health .............................................................................. Michigan Department of Health and Human Services ........................................................................ Mississippi State Department of Health .............................................................................................. New Jersey Department of Health and Senior Services .................................................................... New York City Department of Health and Mental Hygiene ................................................................ New York State Department of Health ................................................................................................ North Carolina Department of Health and Human Services ............................................................... Oregon Health Authority ...................................................................................................................... Pennsylvania Department of Health .................................................................................................... Philadelphia Department of Public Health ........................................................................................... Puerto Rico Department of Health ...................................................................................................... San Francisco Department of Public Health ....................................................................................... Texas Department of State Health Services ....................................................................................... Virginia Department of Health ............................................................................................................. Washington State Department of Health ............................................................................................. Period of Performance: June 1, 2025, through May 31, 2030. Authority: This program is authorized under Section 318 of the Public Health Service Act (42 U.S.C. 247c, as amended). Dated: August 21, 2024. Terrance Perry, Acting Director, Office of Grants Services, Centers for Disease Control and Prevention. [FR Doc. 2024–19298 Filed 8–27–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Proposed Information Collection Activity; Title IV–E Programs Quarterly Financial Report (0970–0510) Children’s Bureau, Administration on Children, Youth and Families, Administration for Children and Families, Department of Health and Human Services. ACTION: Request for public comments. AGENCY: The Administration for Children and Families (ACF) Children’s SUMMARY: 68907 Bureau plans to submit revisions to an approved generic information collection (GenIC) under the umbrella generic: Generic Clearance for Financial Reports used for ACF Non-Discretionary Grant Programs (0970–0510). This request revises form CB–496, the Title IV–E Programs Quarterly Financial Report, used by title IV–E agencies to submit financial claims for the title IV–E entitlement grant programs. DATES: Comments due within 14 days of publication. In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above and below. ADDRESSES: Copies of the proposed collection of information can be obtained and comments may be forwarded by emailing infocollection@ acf.hhs.gov. All requests should be identified by the title of the information collection. SUPPLEMENTARY INFORMATION: Description: ACF programs require detailed financial information from their grantees that allows ACF to monitor various specialized cost categories within each program, to closely manage $955,472 687,266 390,713 1,034,315 817,044 738,464 516,350 514,626 874,378 688,444 489,198 898,374 1,306,704 594,625 687,023 794,810 524,656 579,853 431,047 643,882 735,652 664,068 738,592 program activities, and to have sufficient financial information to enable periodic thorough and detailed audits. Generic Clearance for Financial Reports used for ACF Non-Discretionary Grant Programs allows ACF programs to efficiently develop and receive approval for financial reports that are tailored to specific funding recipients and the associated needs of the program. For more information about the umbrella generic, see: https://www.reginfo.gov/ public/do/PRAViewDocument?ref_ nbr=202108-0970-002 This specific GenIC collects quarterly cost and caseload data for five title IV– E programs (i.e., foster care, adoption assistance, guardianship assistance, prevention services, and kinship navigator). The requested changes include removing reporting items no longer needed, and the addition or revision of reporting lines and instructions required due to recent changes in program regulations, policy guidance, and other operational changes for which further information will enhance the administration of the program. Respondents: Title IV–E agencies khammond on DSKJM1Z7X2PROD with NOTICES ANNUAL BURDEN ESTIMATES Title of information collection Number of respondents Annual frequency of responses Hourly burden per response Annual hourly burden Form CB–496 .................................................................................................. 67 4 23 6154 VerDate Sep<11>2014 18:13 Aug 27, 2024 Jkt 262001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 E:\FR\FM\28AUN1.SGM 28AUN1 68908 Federal Register / Vol. 89, No. 167 / Wednesday, August 28, 2024 / Notices Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 14 days of this publication. Authority: 42 U.S.C. 671(a)(6), 42 U.S.C. 671(a)(7), 42 U.S.C. 673(a)(8)(B) and 42 U.S.C. 674(a) and (b) Mary C. Jones, ACF/OPRE Certifying Officer. [FR Doc. 2024–19253 Filed 8–27–24; 8:45 am] BILLING CODE 4184–73–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2024–N–0008] Patient Engagement Advisory Committee; Notice of Meeting— Patient-Centered Informed Consent in Clinical Study AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Patient Engagement Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to the Agency on FDA’s regulatory issues. The meeting will be open to the public. DATES: The meeting will be held on October 30, 2024, from 10 a.m. to 5 p.m. Eastern Time. ADDRESSES: All meeting participants will be heard, viewed, captioned, and recorded for this advisory committee meeting via an online teleconferencing and/or video conferencing platform. Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: https://www.fda.gov/Advisory Committees/AboutAdvisoryCommittees/ ucm408555.htm. khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:13 Aug 27, 2024 Jkt 262001 FOR FURTHER INFORMATION CONTACT: Letise Williams, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5407, Silver Spring, MD 20993–0002, Letise.Williams@ fda.hhs.gov, 301–796–8398, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last-minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s website at https:// www.fda.gov/AdvisoryCommittees/ default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before the meeting. SUPPLEMENTARY INFORMATION: Agenda: The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. On October 30, 2024, the Committee will discuss and make recommendations on ‘‘PatientCentered Informed Consent in Clinical Study of FDA-Regulated Medical Products.’’ The individuals who volunteer to participate in clinical research play an integral role in advancing scientific knowledge and supporting the development of potentially life-saving therapies for patients in need. Informed consent is a key element in clinical studies and can be one of a patient’s first interactions with the clinical community. Too often, however, informed consent forms are lengthy and difficult for potential research participants to understand. FDA has worked to improve informed consent over the years, including several recent activities such as developing a draft guidance in identifying key information in informed consent. The Committee will provide recommendations on the informed consent process and the areas of focus of the informed consent. The Committee will also provide recommendations on factors to consider when communicating informed consent to clinical study participants to increase the likelihood of participants understanding the key elements of research. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 meeting, the background material will be made publicly available on FDA’s website at the time of the advisory committee meeting, and the background material will be posted on FDA’s website after the meeting. Background material and the link to the online teleconference and/or video conference meeting will be available at https:// www.fda.gov/AdvisoryCommittees/ Calendar/default.htm. Scroll down and select the appropriate advisory committee meeting link. The meeting will include slide presentations with audio and video components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee. Written submissions may be made to the contact person (see FOR FURTHER INFORMATION CONTACT) on or before October 3, 2024. Oral presentations from the public will be scheduled between approximately 2 p.m. and 3 p.m. Eastern Time. Those individuals interested in making formal oral presentations should notify the contact person (see FOR FURTHER INFORMATION CONTACT) and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before September 25, 2024. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. If the number of registrants requesting to speak during the open public hearing is greater than can be reasonably accommodated during the scheduled open hearing portion of the advisory committee meeting, FDA may conduct a lottery to determine the speakers who will be invited to participate. The contact person will notify interested persons regarding their request to speak by September 26, 2024. Virtual Breakout Session: Individuals interested in participating in the virtual breakout scenario discussions will need to sign up to participate on or before October 16, 2024. The signup sheet, as well as additional information pertaining to the virtual scenario discussions, will be available at https:// www.fdalive.com/peac. Everyone who signs up in advance and provides a valid email address will receive an E:\FR\FM\28AUN1.SGM 28AUN1

Agencies

[Federal Register Volume 89, Number 167 (Wednesday, August 28, 2024)]
[Notices]
[Pages 68907-68908]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-19253]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families


Proposed Information Collection Activity; Title IV-E Programs 
Quarterly Financial Report (0970-0510)

AGENCY: Children's Bureau, Administration on Children, Youth and 
Families, Administration for Children and Families, Department of 
Health and Human Services.

ACTION: Request for public comments.

-----------------------------------------------------------------------

SUMMARY: The Administration for Children and Families (ACF) Children's 
Bureau plans to submit revisions to an approved generic information 
collection (GenIC) under the umbrella generic: Generic Clearance for 
Financial Reports used for ACF Non-Discretionary Grant Programs (0970-
0510). This request revises form CB-496, the Title IV-E Programs 
Quarterly Financial Report, used by title IV-E agencies to submit 
financial claims for the title IV-E entitlement grant programs.

DATES: Comments due within 14 days of publication. In compliance with 
the requirements of the Paperwork Reduction Act of 1995, ACF is 
soliciting public comment on the specific aspects of the information 
collection described above and below.

ADDRESSES: Copies of the proposed collection of information can be 
obtained and comments may be forwarded by emailing 
[email protected]. All requests should be identified by the 
title of the information collection.

SUPPLEMENTARY INFORMATION: 
    Description: ACF programs require detailed financial information 
from their grantees that allows ACF to monitor various specialized cost 
categories within each program, to closely manage program activities, 
and to have sufficient financial information to enable periodic 
thorough and detailed audits. Generic Clearance for Financial Reports 
used for ACF Non-Discretionary Grant Programs allows ACF programs to 
efficiently develop and receive approval for financial reports that are 
tailored to specific funding recipients and the associated needs of the 
program. For more information about the umbrella generic, see: https://www.reginfo.gov/public/do/PRAViewDocument?ref_nbr=202108-0970-002
    This specific GenIC collects quarterly cost and caseload data for 
five title IV-E programs (i.e., foster care, adoption assistance, 
guardianship assistance, prevention services, and kinship navigator). 
The requested changes include removing reporting items no longer 
needed, and the addition or revision of reporting lines and 
instructions required due to recent changes in program regulations, 
policy guidance, and other operational changes for which further 
information will enhance the administration of the program.
    Respondents: Title IV-E agencies

                                             Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
                                                                    Annual
       Title of information collection           Number of       frequency of    Hourly burden    Annual hourly
                                                respondents       responses       per response        burden
----------------------------------------------------------------------------------------------------------------
Form CB-496.................................              67                4               23             6154
----------------------------------------------------------------------------------------------------------------


[[Page 68908]]

    Comments: The Department specifically requests comments on (a) 
whether the proposed collection of information is necessary for the 
proper performance of the functions of the agency, including whether 
the information shall have practical utility; (b) the accuracy of the 
agency's estimate of the burden of the proposed collection of 
information; (c) the quality, utility, and clarity of the information 
to be collected; and (d) ways to minimize the burden of the collection 
of information on respondents, including through the use of automated 
collection techniques or other forms of information technology. 
Consideration will be given to comments and suggestions submitted 
within 14 days of this publication.
    Authority: 42 U.S.C. 671(a)(6), 42 U.S.C. 671(a)(7), 42 U.S.C. 
673(a)(8)(B) and 42 U.S.C. 674(a) and (b)

Mary C. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2024-19253 Filed 8-27-24; 8:45 am]
BILLING CODE 4184-73-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.